Search

Introduction: Non-alcoholic fatty liver disease (NAFLD) includes a range of diseases directly related to metabolic syndrome and insulin resistance, and its incidence among patients with type 2 diabetes is increasing. Various non-invasive markers for predicting fibrosis, the risk of progression to cirrhosis or severe metabolic disorders are being extensively studied for prevention, monitoring and treatment. Objective: To investigate serum levels of Fetuin-A, angiopoietin-related growth factor (AGF), and sex hormone binding globulin (SHBG) and to assess their relationship to metabolic disorders and to major indicators of micro and macroangiopathy in patients with obesity and NAFLD. Materials and methods: The studied clinical contingent included 82 patients with NAFLD and obesity, of which 46 were without carbohydrate disorders and 36 were with prediabetes. Serum levels of Fetuin-A, AGF and SHBG were measured by enzyme-linked immunosorbent assay (ELISA). Results: A positive correlation was found between AGF and waist/hip ratio (r =0,255), as well as a negative correlation between SHBG and waist circumference (r =-285) and waist/hip ratio (r=-0,245). There was a weak correlation between Fetuin-A and the ankle-brachial index (r=0,221). No significant differences were found between the studied parameters in the groups with and without prediabetes, as well as with the components of metabolic syndrome. Conclusion: Fetuin-A, AGF and SHBG levels are not affected by carbohydrate disorders and the presence of metabolic syndrome in obese patients and NAFLD. The studied hepatokines did not affect the indicators of micro and macroangiopathy. [ABSTRACT FROM AUTHOR]